PLOS ONE: 极低的低密度脂蛋白浓度与发生2型糖尿病之间的关系

2018-09-23 MedSci MedSci原创

他汀类药物临床试验和孟德尔随机研究的相关结果表明,低密度脂蛋白(LDL-C)浓度降低可能与2型糖尿病(T2DM)风险增加有关。因此研究人员希望通过本项研究进行相关验证。

背景
他汀类药物临床试验和孟德尔随机研究的相关结果表明,低密度脂蛋白(LDL-C)浓度降低可能与2型糖尿病(T2DM)风险增加有关。因此研究人员希望通过本项研究进行相关验证。

方法和发现
研究人员通过范德比尔特大学医学中心的电子健康记录(EHR)来进行患者低密度脂蛋白和正常样本组数据的收集。研究人员使用logistic回归分析低浓度和正常LDL-C组中T2DM的患病率,并调整年龄,种族,性别,体重指数(BMI),高密度脂蛋白胆固醇,甘油三酯和护理持续时间等混杂因素来增加研究结果的可信度。研究结果发现,与正常LDL-C组相比,低浓度LDL-C的患者T2DM的发生风险增加很明显([OR] 2.06,95%CI 1.80-2.37; P < 0.001)。低LDL-C水平与T2DM之间的关联在男性中更为显着(OR 2.43,95%CI 2.00-2.95; P < 0.001); 低LDL-C与体重也存在明显相关性:正常体重(OR 2.18,95%CI 1.59-2.98; P <0.001=,超重(OR 2.17,95%CI 1.65-2.83; P<0.001=和肥胖(OR 2.00,95%CI 1.65-2.41; P<0.001=;同时研究人员观察到低LDL-C与2型糖尿病(T2DM)发生的风险在欧洲血统的个体中更为显着(OR 2.67,95%CI 2.25-3.17; P < 0.001) 。

结论
在没有他汀类药物治疗的情况下极低LDL-C浓度与T2DM发生的风险显着相关,当然这需要进一步的研究进行验证。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1790266, encodeId=d3d31e9026666, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Aug 10 18:57:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424717, encodeId=dd0f1424e1709, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Tue Sep 25 07:57:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544549, encodeId=31e61544549db, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Sep 25 07:57:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041852, encodeId=378a10418520c, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Sep 23 19:57:00 CST 2018, time=2018-09-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1790266, encodeId=d3d31e9026666, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Aug 10 18:57:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424717, encodeId=dd0f1424e1709, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Tue Sep 25 07:57:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544549, encodeId=31e61544549db, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Sep 25 07:57:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041852, encodeId=378a10418520c, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Sep 23 19:57:00 CST 2018, time=2018-09-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1790266, encodeId=d3d31e9026666, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Aug 10 18:57:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424717, encodeId=dd0f1424e1709, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Tue Sep 25 07:57:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544549, encodeId=31e61544549db, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Sep 25 07:57:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041852, encodeId=378a10418520c, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Sep 23 19:57:00 CST 2018, time=2018-09-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1790266, encodeId=d3d31e9026666, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Aug 10 18:57:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424717, encodeId=dd0f1424e1709, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Tue Sep 25 07:57:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544549, encodeId=31e61544549db, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Sep 25 07:57:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041852, encodeId=378a10418520c, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Sep 23 19:57:00 CST 2018, time=2018-09-23, status=1, ipAttribution=)]
    2018-09-23 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

J Hepatol:肝细胞特异性缺失的IL1-RI,通过阻断IL-1驱动的自体炎症,减轻了肝脏损伤

肝细胞中的IL-1R1通过IL-1驱动的细胞死亡和炎症反应,发挥关键作用

BMJ: 磺脲类药物作为2型糖尿病的二线药物与心血管和低血糖事件发生的风险增加相关

本项研究主要评估与2型糖尿病患者二甲双胍单药治疗相比,加用或转用磺脲类药物是否与心肌梗死,缺血性卒中,心血管死亡,全因死亡和严重低血糖风险增加有关。

Clin Nutr:高剂量氨基酸给药可以促进2型糖尿病患者不依赖于血糖控制的合成代谢反应

外科手术应激会引起患者蛋白质分解代谢和高血糖症,这种情况在2型糖尿病(T2DM)患者中会明显增强,并增加围手术期并发症率。本项研究比较了皮下(SC)胰岛素滑动量表的标准血浆葡萄糖控制方法与围手术期施用高剂量静脉内给予氨基酸(AA)是否可以增加接受严格血浆葡萄糖控制的T2DM患者的蛋白质正氮平衡。